INT23171

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 4.15
Pain Relevance 1.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (NLRP3) signal transduction (NLRP3) cytoplasm (NLRP3)
Anatomy Link Frequency
ileum 1
vertebral artery 1
sympathetic 1
CNS 1
NLRP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 3 100.00 Very High Very High Very High
tetrodotoxin 2 99.84 Very High Very High Very High
antagonist 17 98.44 Very High Very High Very High
Central nervous system 8 98.44 Very High Very High Very High
agonist 11 95.00 High High
Inflammation 56 91.92 High High
Enkephalin 2 82.44 Quite High
anakinra 11 82.32 Quite High
vagus nerve 2 75.04 Quite High
bradykinin 1 74.48 Quite High
Disease Link Frequency Relevance Heat
Syndrome 69 100.00 Very High Very High Very High
Deafness 5 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 85 99.92 Very High Very High Very High
Cryopyrin-associated Periodic Syndromes 34 99.80 Very High Very High Very High
Gallbladder Disease 5 99.52 Very High Very High Very High
Crystal Associated Disease 4 98.76 Very High Very High Very High
Arthropathy 5 98.66 Very High Very High Very High
Amyloidosis 7 98.04 Very High Very High Very High
Coronary Heart Disease 2 97.84 Very High Very High Very High
INFLAMMATION 65 91.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These include the prevention of amyloidosis, the prevention of arthropathy in NOMID, the prevention of neurologic damage, especially hearing loss in MWS and NOMID as well as ocular and other central nervous system (CNS) damage related to NOMID.
Negative_regulation (loss) of MWS in CNS associated with deafness, cryopyrin-associated periodic syndromes, amyloidosis, syndrome, central nervous system and arthropathy
1) Confidence 0.37 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2880341 Disease Relevance 1.79 Pain Relevance 0.24
Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII.
Negative_regulation (inhibits) of AII
2) Confidence 0.21 Published 1997 Journal Drugs Section Abstract Doc Link 9421695 Disease Relevance 0.16 Pain Relevance 0
A constitutively active form of mutated NALP3/cryopyrin, which promotes IL-1?
Negative_regulation (form) of NALP3
3) Confidence 0.19 Published 2007 Journal J Transl Med Section Body Doc Link PMC2176053 Disease Relevance 1.02 Pain Relevance 0.26
In another group of anesthetized dogs, we investigated whether the reduced reactivity to intravertebral AII could be duplicated by giving the AVP antagonist either via the vertebral artery or i.v.
Negative_regulation (reduced) of AII in vertebral artery associated with antagonist
4) Confidence 0.12 Published 1983 Journal Hypertension Section Abstract Doc Link 6654469 Disease Relevance 0 Pain Relevance 0.23
Substitution of Ala7 for Pro7 in AI and AII caused a marked reduced binding of anti-AI and antid-AII antisera, respectively, and it completely abolished crossreactivity of anti-AI with Ala7-AII as well as anti-AII with Ala7-AI.
Negative_regulation (abolished) of AII
5) Confidence 0.12 Published 1990 Journal J. Immunol. Methods Section Abstract Doc Link 2391430 Disease Relevance 0.42 Pain Relevance 0.08
In ileum, AII and AIII were equieffective, and both the maximal response and potency were decreased by tetrodotoxin and atropine.
Negative_regulation (decreased) of AII in ileum associated with tetrodotoxin and potency
6) Confidence 0.07 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8263814 Disease Relevance 0.44 Pain Relevance 0.53
AII acts by stimulating specific receptors, in the human body we are able to distinguish two different types of receptors: AT1 and AT2. the AT1 receptors are responsible for known effects of AII; vasoconstriction, increase of aldosterone activity, myocardial hypertrophy, vessel wall smooth muscle proliferation, renal sodium reabsortion, increase in peripheral noradrenergic activity, vasopresin release, sympathetic stimulation, decrease in renal blood flow, etc.
Negative_regulation (effects) of AII in sympathetic associated with coronary heart disease and increased venous pressure under development
7) Confidence 0.07 Published 2006 Journal Cardiovasc Diabetol Section Body Doc Link PMC1434727 Disease Relevance 0.32 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox